Source Paper
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi, Roger C. Pai, Sharon Fong, Susan Leung, David A. Lawrence et al.
Journal of Clinical Investigation • 1999
Solid Tumor Treatment Study
Objective: Evaluation of Apo2L (TRAIL) treatment on tumor cell apoptosis, progression suppression, and survival improvement in mice bearing solid tumors, including synergistic effects with chemotherapeutic drugs
This is a Solid Tumor Treatment Study protocol using mouse as the model organism. The procedure involves 5 procedural steps, 3 materials. Extracted from a 1999 paper published in Journal of Clinical Investigation.
Model and subjects
mouse • athymic
Study window
Estimated timing pending
Core workflow
In vitro cytotoxicity screening • Tumor xenograft establishment • Apo2L treatment administration
Primary readouts
- Tumor cell apoptosis induction
- Tumor progression suppression
- Survival improvement
- Tumor incidence reduction
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
In vitro cytotoxicity screening
Tested Apo2L effects on 39 cell lines from colon, lung, breast, kidney, brain, and skin cancer to determine cytostatic or cytotoxic effects
Note: Apo2L exerted cytostatic or cytotoxic effects in vitro on 32 of 39 cell lines tested
View evidence from paper
“Apo2L exerted cytostatic or cytotoxic effects in vitro on 32 of 39 cell lines from colon, lung, breast, kidney, brain, and skin cancer”
Tumor xenograft establishment
Injected tumor cells into athymic mice to establish solid tumors
Note: Treatment with Apo2L was administered shortly after tumor xenograft injection
View evidence from paper
“Treatment of athymic mice with Apo2L shortly after tumor xenograft injection markedly reduced tumor incidence”
Apo2L treatment administration
Administered repeated intravenous injections of Apo2L to mice bearing solid tumors
Note: Repeated intravenous injections were used; treatment induced tumor cell apoptosis, suppressed tumor progression, and improved survival
View evidence from paper
“Apo2L treatment of mice bearing solid tumors induced tumor cell apoptosis, suppressed tumor progression, and improved survival”
Combination therapy with chemotherapeutic drugs
Treated mice with Apo2L in combination with 5-fluorouracil or CPT-11 to evaluate synergistic effects
Note: Combination treatment resulted in substantial tumor regression or complete tumor ablation
View evidence from paper
“Apo2L cooperated synergistically with the chemotherapeutic drugs 5-fluorouracil or CPT-11, causing substantial tumor regression or complete tumor ablation”
Toxicity assessment in nonhuman primates
Administered repeated intravenous injections of Apo2L in nonhuman primates to assess safety profile
Note: No detectable toxicity was observed to tissues and organs examined
View evidence from paper
“Repeated intravenous injections of Apo2L in nonhuman primates did not cause detectable toxicity to tissues and organs examined”